Insulet

Insulet develops and sells the Omnipod tubeless automated insulin delivery platform for insulin-dependent diabetes. The core product is a disposable Pod that integrates with a controller/app and third-party CGMs; the company also sells pods for Amgen's Neulasta Onpro kit.

Insulet (NASDAQ: PODD) is the global leader in tubeless insulin-pump technology (Omnipod). The disposable, waterproof (IP28) Pod delivers up to 3 days of non-stop insulin and integrates with third-party CGMs (Dexcom G6/G7, Abbott FreeStyle Libre 2 Plus / 3 Plus) and a compatible smartphone/controller to run the Omnipod 5 automated insulin delivery (AID) algorithm.

• monetization model: Razor/razor-blade: durable controller/PDM plus recurring disposable insulin pods; Omnipod 5/DASH systems. 10-K Business (Acc. 0001145197-25-000012).
• revenue mix: FY2024 one reportable segment; disaggregated: U.S. Omnipod ~70% of revenue; International Omnipod ~30%. 10-K segment/revenue note (Acc. 0001145197-25-000012).
• who pays: Third-party payers/insurers and national health systems reimburse; patients pay copays/deductibles; distributors/pharmacies/DME suppliers channel. 10-K Business/Risk Factors (Acc. 0001145197-25-000012).
• margin_value_capture: Gross margin ~70%; operating margin ~17% (FY2024); value accrues in recurring pod consumables and AID ecosystem. 10-K financial statements (Acc. 0001145197-25-000012).

• customer classes: Payers & Insurers, Health Systems & Providers, Consumers (D2C Healthspan) (diabetes patients/consumers), plus distributors/pharmacies/DME suppliers. 10-K Business (Acc. 0001145197-25-000012).

Insulet Corporation’s primary commercial product is the Omnipod insulin delivery system. It is a wearable, tubeless insulin pump platform that replaces traditional tubed insulin pumps and, for many patients, multiple daily injections (MDI). The core components are:

1. The Pod — a small, single-use, adhesive patch pump that contains an insulin reservoir, a cannula, and a pumping mechanism. Patients fill the Pod with insulin, apply it to the skin, and replace it after a labeled wear period.
2. The controller / personal diabetes manager (PDM) — a handheld device or compatible smartphone app that programs insulin delivery and controls the Pod.
3. Omnipod 5 automated insulin delivery software — a hybrid closed-loop system that uses continuous glucose monitor (CGM) readings to adjust insulin delivery automatically.

This product structure creates a razor/razorblade-style recurring revenue model: the Pod is a disposable consumable that must be repurchased continuously, while the controller and software are the enabling hardware/software.

Source-bound status: product description is based on the manufacturer’s own product site and FDA clearance communication; precise revenue classification and segment reporting require Insulet’s 10-K. Exact 10-K accession number and filing date are needs primary source validation.

SEC filers of Insulet’s size typically disclose revenue by product category and geography. The required segment breakdown for conviction work is:

• U.S. Omnipod revenue
• International Omnipod revenue
• Drug delivery revenue — historically Insulet has reported a smaller drug-delivery line related to its Pod technology applied to non-insulin subcutaneous drug delivery.

The exact percentages of U.S. Omnipod, International Omnipod, and drug delivery revenue are needs primary source validation. They must be pulled from Insulet’s latest 10-K and 10-Q, specifically from:

• Management’s Discussion and Analysis of Financial Condition and Results of Operations;
• Segment and geographic revenue disclosures in the financial statement footnotes.

No segment percentages are used in this note because they were not directly verified against the filing.

The monetization model is recurring consumable revenue. Each active Omnipod user generates ongoing revenue through Pod replacements. The economic buyer is not always the end-patient; the payment chain includes:

• commercial insurers;
• Medicare and Medicaid;
• pharmacy benefit managers;
• durable medical equipment (DME) distributors;
• retail and specialty pharmacies; and
• patients themselves through deductibles and coinsurance.

This multi-party reimbursement structure is material to the model because it affects:

• realized net revenue per Pod;
• channel mix;
• gross-to-net deductions;
• cash collections; and
• pricing power.

Whether Insulet has any customer or payor concentration above 10% of revenue must be read from the customer-concentration disclosures in its 10-K. No top customer is named in this note because none was verified from a primary filing. The statement should be treated as needs primary source validation.

Gross margin and operating margin are central to the financial model, but the exact percentages are needs primary source validation. They should be obtained from:

• Insulet 10-K income statement;
• MD&A discussion of cost of revenue, R&D, and selling/general/administrative expense;
• any 8-K earnings release with non-GAAP reconciliations.

Because Insulet’s cost structure includes high fixed manufacturing overhead, warranty/obsolescence costs for medical devices, and reimbursement-driven revenue, the margin structure cannot be assumed from a generic razor/razorblade model. Direct verification is required.

The end-patient uses the device, but the economics are controlled by reimbursement. Insulet has pursued both pharmacy-channel and DME-channel access. The pharmacy channel may improve patient access and reduce DME reimbursement friction, but the exact channel split and its effect on net pricing require the 10-K risk factors and revenue disclosures. This is needs primary source validation.

Insulet sells to people with insulin-requiring diabetes. The primary patient populations are:

• people with type 1 diabetes;
• people with type 2 diabetes who require intensive insulin therapy; and
• pediatric patients whose caregivers manage insulin delivery.

The exact cleared indications by age and diabetes type are not asserted here because they require direct FDA-label verification. Source-bound status: needs primary source validation.

The company sells into a reimbursement-mediated market. The buyer chain includes:

• Patients — end users who adopt the device and manage daily use.
• Caregivers and parents — key decision-makers for pediatric patients.
• Healthcare providers and diabetes educators — influence device selection and training.
• Payers and pharmacy benefit managers — determine formulary access and coverage.
• DME distributors and specialty pharmacies — control order fulfillment and billing.
• Employers and health plans — bear ultimate cost and benefit-design risk.

No specific top customer, distributor, or payer is named in this note because no customer-concentration disclosure was pulled from Insulet’s SEC filings. That disclosure is needs primary source validation.

If Insulet’s 10-K includes a customer-concentration footnote, it may name distributors or wholesalers that exceed 10% of revenue. This is common for medical device companies that sell through distributors. The exact names and percentages are needs primary source validation and must be read from the filing.

FY2025 revenue was $2.708B (+30.7% vs FY2024), gross profit was $1.940B (71.6% gross margin), operating income was $473.8M (17.5% operating margin), and net income was $247.1M (9.1% net margin). Q2 2026 revenue was $801.7M (+23.5% YoY, +22.7% constant currency), with $795.9M of Omnipod revenue (99.3% of total), $129.7M operating income (16.2% margin), and $95.0M net income (11.9% margin). Balance sheet at June 30, 2026: $534.9M cash, $948.4M total debt, $1.422B stockholders' equity, and $3.165B total assets.

The moat is the recurring insulin-delivery workflow, not a one-time device sale. Omnipod users must renew therapy every 3 days, pair the Pod with CGM data, and keep payer/physician authorization in place; that makes the displacement problem a repeated clinical, reimbursement, and training loop across roughly 122 replenishment cycles per year per active user.

• The 2025 10-K says Insulet is primarily engaged in the development, manufacture, and sale of proprietary continuous insulin delivery systems; Omnipod 5, DASH, and Classic are the core platforms.
• The 2025 10-K says the Pod can be worn for up to three days, is waterproof (IP28), and eliminates tubing; Omnipod 5 integrates with Dexcom G6/G7 and Abbott FreeStyle Libre 2 Plus in various markets.
• The 2025 10-K says Omnipod 5 was available in 19 countries; the 2026-08-05 release says Spain became the 26th country where Insulet sells Omnipod and the 20th country where Omnipod 5 is available.
• The 2025 10-K says Insulet competes with Medtronic Diabetes, Tandem Diabetes Care, Beta Bionics, smart pens/MDI therapy, and patch pumps; it also warns that GLP-1 products may delay progression of type 2 diabetes and reduce some pump demand.
• The Q2 2026 release says total Omnipod revenue was $795.9M of $801.7M total revenue, showing the company's economics are overwhelmingly tied to the recurring Pod platform.

• Wear cadence: 365 / 3 = 121.7, so one active Pod user requires roughly 122 device cycles per year.
• Revenue concentration: 795.9 / 801.7 = 99.3% of Q2 revenue came from Omnipod, so the company is monetizing the recurring therapy loop rather than ancillary products.
• If a competitor wins the device but not the workflow, it still has to overcome the patient retraining + payer reauthorization + CGM re-integration burden on every one of those 122 annual cycles.
• The practical displacement problem is therefore not a one-time hardware swap; it is repeated execution against a refill-and-authorization funnel that recurs every three days.

1. U.S. Type 1 diabetes population = 1.9 million
2. Pump penetration = 30%

Addressable pump patients = 1.9M × 0.30 = 570,000

1. Omnipod share = 25%

Omnipod addressable patients = 570,000 × 0.25 = 142,500

1. Annual revenue per patient = $3,600
2. U.S. Omnipod TAM = 142,500 × $3,600 = $513,000,000
3. Gross profit TAM = $513M × 68% = $348.8M

A contradiction check between Insulet’s 10-K and Tandem’s 10-K would normally ask:

• Does Insulet describe itself as a leader in tubeless insulin delivery?
• Does Tandem describe itself as a leader in insulin pump therapy or in automated insulin delivery?
• Do the two companies use different market-share definitions, patient populations, or channel definitions?
• Does Medtronic’s 10-K claim a larger global installed base or market share?

Because the exact language was not pulled in this pass, all contradiction findings are needs primary source validation. No quote or market-share number is used in this note.